J4

• 临床医学 • Previous Articles     Next Articles

  

  • Received:2005-07-30 Revised:1900-01-01 Online:2006-09-28 Published:2006-09-28

Abstract: Abstract:Objective To study the clinical significances of serum FT3, FT4, sTSH, TRAb, TGA and TMA concentration changes in Graves’ patients before and after 131I treatment.Methods The serum FT3, FT4, sTSH, TRAb, TGA and TMA concentrations before treatment, 3,6,12 and 18 months after therapy in 172 Graves’ patients and 43 normal controls were obtained by time-resolved fluoroimmunoassay technique. Results FT3 and FT4 concentrations showed an obvious decrease 3 months after treatment, while sTSH and TRAb had remarkable high values, as TGA and TMA demonstrated a trend to increase. FT3, FT4 and sTSH concentrations were close to control group 6 months after treatment, TRAb had a decline trend.All the six indexes approached to normal 18 months after treatment. Conclusion It is of great of significance for the Graves’ patients to accept the developmental observation of serum FT3, FT4, and sTSH, TRAb, TGA and TMA concentrations before and after 131I therapy, which provides a great of positive information for therapy guiding, observation and prognosis.

Key words: 131<, sup>I therapy, FT3<, sub>, FT4<, sub>, sTSH, TRAb, TGA, TMA, radioimmunoassay, autoantibodies

CLC Number: 

  • R581.1